New Strategies in Bladder Cancer: A Second Coming for Immunotherapy

Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinum-based chemotherapy, which has been the standard-of-care in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therap...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2016-02, Vol.22 (4), p.793-801
Main Authors: Ghasemzadeh, Ali, Bivalacqua, Trinity J, Hahn, Noah M, Drake, Charles G
Format: Article
Language:English
Subjects:
Animals
Cancer Vaccines - therapeutic use
Combined Modality Therapy
Humans
Immunotherapy
Tumor Microenvironment - immunology
Urinary Bladder Neoplasms - immunology
Urinary Bladder Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinum-based chemotherapy, which has been the standard-of-care in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system have led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines and highlight several additional immunotherapy modalities in early stages of development.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.ccr-15-1135